17 patients were identified (59% female, median age 70, range 41-85) with ICI associated CNP. Cancers included; melanoma (11 [65%]), genitourinary (3 [18%]), lung (2 [12%]), laryngeal (1[6%]). CNPs included; facial (11, [65%]), optic (3, [18%]), abducens (1, [6%]), vestibulocochlear (1, [6%]), trochlear (1, [6%]). ICIs included; pembrolizumab (5 [29%], combined ipilimumab/nivolumab (5 [29%], nivolumab (4 [23%]), ipilimumab (2 [12%]) and nivolumab/relatlimab (1 [6%]). Symptoms emerged at median of 25 days (range 1-110) after the last ICI dose, and median of 96 days (range 12-546) and 6 cycles (IQR 3-9) from the initiation of ICI. 

There were 11 (69%) with available concurrent MRI with 5 (45%) demonstrating abnormal findings (enhancement of; IAC [2], facial and vestibulocochlear [1], oculomotor, trigeminal, bilateral facial [1] and brain metastatic disease [1]).  

Treatments included corticosteroids in 13, one patient had additional IVIG. Clinical outcomes included; complete resolution (6), partial improvement (7), permanent visual loss (2), permanent hearing loss (1) and recurrent facial nerve palsy (1). Of those treated, 7/13 [54%] improved.  Melanoma patients with CNP irAE compared to melanoma patients without irAE had improved survival (p=0.044).